Literature DB >> 2462295

Effects of cimetidine, progesterone, cannitracin and tolazoline on the weight and DNA content of the testosterone-induced hyperplastic prostate of the rat.

W Chen1, X M Zhou, D Y Chen, J S Kang.   

Abstract

The antiandrogenic potency of cimetidine, progesterone, cannitracin and tolazoline was studied in intact immature rats by determination of the weight and DNA content of the ventral prostate. Cimetidine is a H-2-receptor histamine antagonist, cannitracin is an antifungal antibiotic derived from Strp-griseus and tolazoline is an alpha-adrenergic blocker similar to phentolamine. All rats (except the control group) received testosterone propionate (TP) 0.3 mg s.c. with the drugs above every day for one week. Cimetidine, progesterone and cannitracin, but not tolazoline, significantly decreased the weight and DNA content of the hyperplastic prostate induced by TP. The results indicate that cimetidine, progesterone and cannitracin have an antiandrogenic effect. This study provides the basis for investigating the effects of antiandrogen in men with symptomatic benign prostatic hyperplasia.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2462295     DOI: 10.1007/bf00256043

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  20 in total

1.  Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck.

Authors:  M Caine; S Raz; M Zeigler
Journal:  Br J Urol       Date:  1975-04

2.  A SEARCH FOR INHIBITORS OF PROSTATE GROWTH STIMULATORS.

Authors:  C TESAR; W W SCOTT
Journal:  Invest Urol       Date:  1964-03

3.  TREATMENT OF BENIGN PROSTATIC HYPERTROPHY WITH HYDROXYPROGESTERONE CAPROATE: EFFECT ON CLINICAL SYMPTOMS, MORPHOLOGY, AND ENDOCRINE FUNCTION.

Authors:  J GELLER; R BORA; T ROBERTS; H NEWMAN; A LIN; R SILVA
Journal:  JAMA       Date:  1965-07-12       Impact factor: 56.272

4.  Biological actions of 17 alpha-(2-methallyl)-19-nortes-tosterone, an orally active progestational agent.

Authors:  R L ELTON; R A EDGREN
Journal:  Endocrinology       Date:  1958-10       Impact factor: 4.736

5.  The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy.

Authors:  M Caine
Journal:  J Urol       Date:  1986-07       Impact factor: 7.450

6.  The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro.

Authors:  N Bruchovsky; J D Wilson
Journal:  J Biol Chem       Date:  1968-04-25       Impact factor: 5.157

7.  Pharmacological receptors in the prostate.

Authors:  S Raz; M Zeigler; M Caine
Journal:  Br J Urol       Date:  1973-12

8.  Medrogestone: a prospective study in the pharmaceutical management of benign prostatic hyperplasia.

Authors:  D F Paulson; R D Kane
Journal:  J Urol       Date:  1975-06       Impact factor: 7.450

9.  Candicidin treatment of prostatism: a prospective double-blind placebo-controlled study.

Authors:  K M Jensen; P O Madsen
Journal:  Urol Res       Date:  1983

10.  Supranormal nuclear content of 5 alpha-dihydrotestosterone in benign hyperplastic prostate of humans.

Authors:  A W Meikle; E S Collier; R G Middleton; S M Fang
Journal:  J Clin Endocrinol Metab       Date:  1980-10       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.